These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Prevention of early-onset group B streptococcus neonatal diseases. The 2005 experience of the Lille University Health Center].
    Author: Thibaudon Baveux C, Stroebel Noguer A, Boulard Mallet I, Djavadzadeh-Amini M, Kacet N, Truffert P, Subtil D, Dubos JP.
    Journal: J Gynecol Obstet Biol Reprod (Paris); 2008 Jun; 37(4):392-9. PubMed ID: 18243572.
    Abstract:
    OBJECTIVES: To study the efficiency of the official recommendations on the prevention of group B streptococcus and the impact of this strategy. MATERIALS AND METHODS: A prospective study was realized in 2005. All infants who were live-born at the Jeanne-de-Flandre hospital (Lille, France) and their mothers were included in the study. Data concerned both pregnancy (vaginal screening, intrapartum antibiotic) and newborn (safe, colonization and early-onset neonatal bacterial disease). RESULTS: Our study included 4353 mother-newborn couples. Vaginal screening was performed on 92% of the women included in the study. Prevalence of vaginal group B streptococcus in screened women was 7%. Perpartum antibioprophylaxia of group B streptococcus was achieved in 12% of the women included in the study. Group B streptococcus was associated to 60% of probable and certain early-onset bacterial neonatal diseases, with an incidence of 9/1000 births. Exposition to antenatal antibiotherapy multiplied by two the risk of ampicillin resistant Gram-negative bacilli (RR=2 [1.1-3.8]). CONCLUSION: Recommendations were well followed, but in our health center group, B streptococcus was the main bacteria responsible for early-onset bacterial neonatal diseases. Because of the risk of germ selection, a more targeted antibioprophylaxia has to be preferred.
    [Abstract] [Full Text] [Related] [New Search]